Biotechnology firm Transgenomic, Inc. (TBIO.OB, TBIO) Monday said it is collaborating with Amgen Inc. (AMGN) to develop a CE-IVD test to screen patients with metastatic colorectal cancer for RAS mutations. These RAS mutations, identified using the CE-IVD CRC RAScan kits which use Surveyor-Wave technology, provide physicians with important information regarding tumor mutation status to inform clinical treatment decisions for their mCRC patients, added the company. Financial terms of the agreement were not disclosed.
Commenting on the development, Craig Tuttle, Chief Executive Officer of Transgenomic said, "This collaboration with Amgen is indicative of how Transgenomic's proprietary molecular technologies are advancing personalized medicine...This highly precise, innovative test was developed at Transgenomic's laboratories, which excel in genomic and genetic analysis, novel technology development, and its application in clinical research and trials."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.